189 related articles for article (PubMed ID: 19479249)
21. The asymmetry of neural symptoms in Wilson's disease patients detecting by diffusion tensor imaging, resting-state functional MRI, and susceptibility-weighted imaging.
Zhou XX; Li XH; Chen DB; Wu C; Feng L; Chu JP; Yang ZY; Li XB; Qin H; Li GD; Huang HW; Liang YY; Liang XL
Brain Behav; 2018 May; 8(5):e00930. PubMed ID: 29761003
[TBL] [Abstract][Full Text] [Related]
22. Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap.
Sinha S; Taly AB
J Neurol Sci; 2008 Jan; 264(1-2):129-32. PubMed ID: 17765927
[TBL] [Abstract][Full Text] [Related]
23. Wilson's disease: long-term follow-up of a cohort of 24 patients treated with D-penicillamine.
Lowette KF; Desmet K; Witters P; Laleman W; Verslype C; Nevens F; Fevery J; Cassiman DM
Eur J Gastroenterol Hepatol; 2010 May; 22(5):564-71. PubMed ID: 20042865
[TBL] [Abstract][Full Text] [Related]
24. Resolution of cranial MRI and SPECT abnormalities in a patient with Wilson's disease following oral zinc monotherapy.
Ishida S; Doi Y; Yamane K; Sugino M; Kimura F; Hanafusa T; Fukui H; Tamai H
Intern Med; 2012; 51(13):1759-63. PubMed ID: 22790141
[TBL] [Abstract][Full Text] [Related]
25. Neurological manifestations in Wilson's disease: Report of 119 cases.
Machado A; Chien HF; Deguti MM; Cançado E; Azevedo RS; Scaff M; Barbosa ER
Mov Disord; 2006 Dec; 21(12):2192-6. PubMed ID: 17078070
[TBL] [Abstract][Full Text] [Related]
26. Mid-brain pathology of Wilson's disease: MRI analysis of three cases.
Hitoshi S; Iwata M; Yoshikawa K
J Neurol Neurosurg Psychiatry; 1991 Jul; 54(7):624-6. PubMed ID: 1895127
[TBL] [Abstract][Full Text] [Related]
27. Neurological features and outcomes of Wilson's disease: a single-center experience.
Samanci B; Sahin E; Bilgic B; Tufekcioglu Z; Gurvit H; Emre M; Demir K; Hanagasi HA
Neurol Sci; 2021 Sep; 42(9):3829-3834. PubMed ID: 33474589
[TBL] [Abstract][Full Text] [Related]
28. Resolution of cerebral white matter lesions following long-term penicillamine therapy for Wilson's disease: report of a case.
Huang CC; Chu NS
J Formos Med Assoc; 1992 Jun; 91(6):627-9. PubMed ID: 1358351
[TBL] [Abstract][Full Text] [Related]
29. Initial and follow-up brain MRI findings and correlation with the clinical course in Wilson's disease.
Roh JK; Lee TG; Wie BA; Lee SB; Park SH; Chang KH
Neurology; 1994 Jun; 44(6):1064-8. PubMed ID: 8208401
[TBL] [Abstract][Full Text] [Related]
30. [Cerebral magnetic resonance in Wilson's disease].
Amato C; Bisceglie P; Moschini M
Radiol Med; 1994 Dec; 88(6):752-7. PubMed ID: 7878232
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors in patients presenting with severe neurological forms of Wilson's disease.
Prashanth LK; Taly AB; Sinha S; Ravishankar S; Arunodaya GR; Vasudev MK; Swamy HS
QJM; 2005 Aug; 98(8):557-63. PubMed ID: 16006499
[TBL] [Abstract][Full Text] [Related]
32. Brain microstructural abnormalities in patients with Wilson's disease: A systematic review of diffusion tenor imaging studies.
Karimi A; Mohammadi S; Salehi MA; Dager SR
Brain Imaging Behav; 2022 Dec; 16(6):2809-2840. PubMed ID: 36327021
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of Wilson's disease with penicillamine and zinc salts: a follow-up study].
Li M; Zhang YH; Qin J
Zhonghua Er Ke Za Zhi; 2003 Feb; 41(2):119-22. PubMed ID: 14759316
[TBL] [Abstract][Full Text] [Related]
34. Magnetic Susceptibility Changes in the Basal Ganglia and Brain Stem of Patients with Wilson's Disease: Evaluation with Quantitative Susceptibility Mapping.
Doganay S; Gumus K; Koc G; Bayram AK; Dogan MS; Arslan D; Gumus H; Gorkem SB; Ciraci S; Serin HI; Coskun A
Magn Reson Med Sci; 2018 Jan; 17(1):73-79. PubMed ID: 28515413
[TBL] [Abstract][Full Text] [Related]
35. [A study of trientine therapy in Wilson's disease with neurological symptoms].
Suda M; Kubota J; Yamaguchi Y; Fujioka Y; Saito Y; Aoki T
No To Hattatsu; 1993 Sep; 25(5):429-34. PubMed ID: 8398232
[TBL] [Abstract][Full Text] [Related]
36. Brain magnetic resonance imaging and severity of neurological disease in Wilson's disease - the neuroradiological correlations.
Rędzia-Ogrodnik B; Członkowska A; Bembenek J; Antos A; Kurkowska-Jastrzębska I; Skowrońska M; Smoliński Ł; Litwin T
Neurol Sci; 2022 Jul; 43(7):4405-4412. PubMed ID: 35275318
[TBL] [Abstract][Full Text] [Related]
37. D-penicillamine versus zinc sulfate as first-line therapy for Wilson's disease.
Członkowska A; Litwin T; Karliński M; Dziezyc K; Chabik G; Czerska M
Eur J Neurol; 2014 Apr; 21(4):599-606. PubMed ID: 24447648
[TBL] [Abstract][Full Text] [Related]
38. Long-term outcome of patients with neurological form of Wilson's disease compliant to the de-coppering treatment.
Stanković I; Jovanović Č; Vitković J; Svetel M; Pekmezović T; Tomić A; Kresojević N; Marković V; Ječmenica Lukić M; Petrović I; Dragašević-Mišković N; Kostić V
J Neurol; 2023 Jul; 270(7):3492-3498. PubMed ID: 37016067
[TBL] [Abstract][Full Text] [Related]
39. [Magnetic Resonance Imaging Improvement in a Patient with Wilson's Disease Following Treatment with Trientine Hydrochloride and Zinc Acetate].
Kim Y; Koide R; Kawata A
Brain Nerve; 2015 May; 67(5):635-8. PubMed ID: 25957210
[TBL] [Abstract][Full Text] [Related]
40. Wilson's disease. Development of neurological disease after beginning penicillamine therapy.
Glass JD; Reich SG; DeLong MR
Arch Neurol; 1990 May; 47(5):595-6. PubMed ID: 2334309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
